التجارب السريرية بالأسفل التجارب السريرية الحالية.50 دراسات في عيادة الثدي (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Breast Cancer: Can We Predict Pathological Complete Response following Neoadjuvant Treatment? Scottsdale/Phoenix, Ariz. This project will investigate whether ctDNA analysis in newly diagnosed stage I, II, III breast cancer patients treated with neoadjuvant systemic therapy can predict pathological Complete Response (pCR). A Study to Assess Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally-advanced Breast Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the impact of blood collection tube type and processing methods on ctDNA, evaluate the impact of long-term storage of plasma and extracted DNA, and evaluate ctDNA levels at baseline and during treatment for patients with Stage I-III breast cancer. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). The Use of Topical Tranexamic Acid in Implant-Based Breast Reconstruction with Acellular Dermal Matrix Rochester, Minn. The purpose of this study is to determine whether administration of Topical Transexamic Acid (TXA) at the time of tissue expander placement in the setting of implant-based breast reconstruction reduces postoperative drain volume, as well as reducing the time until drains meet criteria for removal. Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy Rochester, Minn. The goal of this clinical research study is to learn how often breast cancer recurs (returns after treatment) in the breast in patients who have been treated with chemotherapy and have had follow-up radiation therapy (but not surgery) and are in complete remission (no evidence of disease). This is an investigational study. Radiation therapy is delivered using FDA-approved and commercially available methods. The study doctor can explain how radiation therapy is designed to work. About 120 participants will be enrolled on this multicenter study. Up to 90 may take part at MD Anderson. A Study to Evaluate the Safety of the Goldilocks Procedure with Implant-Based Reconstruction Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to assess outcomes, satisfaction and aesthetics of two different breast reconstruction techniques (Goldilocks alone, and Goldilocks with Implant-Based Reconstruction) and compare its safety, patient satisfaction, aesthetic evaluation and complications. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy. GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer. A Study to Evaluate Radiotherapy to the Whole Breast or Post-mastectomy Chest Wall Including Regional Nodal Irradiation Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the safety of 5 fraction vs. 25 fraction radiation to the whole breast or post-mastectomy chest wall/reconstructed chest with regional nodal radiation. 3D Ultrasound Imaging for Breast Cancer Diagnosis Rochester, Minn. The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 التاليالصفحة التالية بالأسفل التجارب السريرية الحالية.50 دراسات في عيادة الثدي (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Breast Cancer: Can We Predict Pathological Complete Response following Neoadjuvant Treatment? Scottsdale/Phoenix, Ariz. This project will investigate whether ctDNA analysis in newly diagnosed stage I, II, III breast cancer patients treated with neoadjuvant systemic therapy can predict pathological Complete Response (pCR). A Study to Assess Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally-advanced Breast Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the impact of blood collection tube type and processing methods on ctDNA, evaluate the impact of long-term storage of plasma and extracted DNA, and evaluate ctDNA levels at baseline and during treatment for patients with Stage I-III breast cancer. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). The Use of Topical Tranexamic Acid in Implant-Based Breast Reconstruction with Acellular Dermal Matrix Rochester, Minn. The purpose of this study is to determine whether administration of Topical Transexamic Acid (TXA) at the time of tissue expander placement in the setting of implant-based breast reconstruction reduces postoperative drain volume, as well as reducing the time until drains meet criteria for removal. A Study to Evaluate the Safety of the Goldilocks Procedure with Implant-Based Reconstruction Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to assess outcomes, satisfaction and aesthetics of two different breast reconstruction techniques (Goldilocks alone, and Goldilocks with Implant-Based Reconstruction) and compare its safety, patient satisfaction, aesthetic evaluation and complications. Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy Rochester, Minn. The goal of this clinical research study is to learn how often breast cancer recurs (returns after treatment) in the breast in patients who have been treated with chemotherapy and have had follow-up radiation therapy (but not surgery) and are in complete remission (no evidence of disease). This is an investigational study. Radiation therapy is delivered using FDA-approved and commercially available methods. The study doctor can explain how radiation therapy is designed to work. About 120 participants will be enrolled on this multicenter study. Up to 90 may take part at MD Anderson. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy. GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer. A Study to Evaluate Radiotherapy to the Whole Breast or Post-mastectomy Chest Wall Including Regional Nodal Irradiation Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the safety of 5 fraction vs. 25 fraction radiation to the whole breast or post-mastectomy chest wall/reconstructed chest with regional nodal radiation. 3D Ultrasound Imaging for Breast Cancer Diagnosis Rochester, Minn. The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 التاليالصفحة التالية طلب تحديد موعد الخبرات والتصنيفاتالأبحاث 26/06/2024 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة عيادة الثديالأقسامطلب تحديد موعد طبيمُلخّصالاختبارات والإجراءاتالحالات التي تمَّ علاجهاالأطباءالأطباء حسب الموقع والتخصصمجموعة متميزةالخبرات والتصنيفاتالتجارب السريريةالأبحاثخبرات Mayo Clinic وقصص المرضىالتكاليف والتأمينالأخبار من Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب تحديد موعد طبيمُلخّصالاختبارات والإجراءاتالحالات التي تمَّ علاجهاالأطباءالأطباء حسب الموقع والتخصصمجموعة متميزةالخبرات والتصنيفاتالتجارب السريريةالأبحاثخبرات Mayo Clinic وقصص المرضىالتكاليف والتأمينالأخبار من Mayo Clinicإحالة المرضى ORG-20459452 الأقسام والمراكز الطبية عيادة الثدي